Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Neurocrine Biosciences (NBIX) EBITDA Margin (2017 - 2026)

Neurocrine Biosciences filings provide 15 years of EBITDA Margin readings, the most recent being 19.07% for Q4 2025.

  • On a quarterly basis, EBITDA Margin rose 403.0% to 19.07% in Q4 2025 year-over-year; TTM through Dec 2025 was 16.99%, a 255.0% increase, with the full-year FY2025 number at 16.99%, up 255.0% from a year prior.
  • EBITDA Margin hit 19.07% in Q4 2025 for Neurocrine Biosciences, down from 26.44% in the prior quarter.
  • In the past five years, EBITDA Margin ranged from a high of 30.36% in Q4 2023 to a low of 99.0% in Q2 2022.
  • Median EBITDA Margin over the past 5 years was 14.79% (2021), compared with a mean of 7.35%.
  • Biggest five-year swings in EBITDA Margin: crashed -14279bps in 2021 and later skyrocketed 12045bps in 2023.
  • Neurocrine Biosciences' EBITDA Margin stood at 3.01% in 2021, then skyrocketed by 866bps to 23.08% in 2022, then skyrocketed by 32bps to 30.36% in 2023, then tumbled by -50bps to 15.04% in 2024, then grew by 27bps to 19.07% in 2025.
  • The last three reported values for EBITDA Margin were 19.07% (Q4 2025), 26.44% (Q3 2025), and 16.15% (Q2 2025) per Business Quant data.